Juan Fernando Sanchez Net Worth

Mr. Juan Fernando Sanchez biography

Juan Fernando Sanchez is the VP of Corp. Communications & Investor Relations at Intra-Cellular Therapies Inc.

How old is Mr Sanchez?

Mr Sanchez is 50, he's been the VP of Corp. Communications & Investor Relations of Intra-Cellular Therapies Inc since . There are 14 older and 2 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.

What's Mr Sanchez's mailing address?

Juan's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK, NY, 10032.

Insiders trading at Intra-Cellular Therapies Inc

Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus a Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.

What does Intra-Cellular Therapies Inc do?

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Intra-Cellular Therapies Inc executives and stock owners

Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:

• Sharon Mates,
  Chairman of the Board, President, Chief Executive Officer
• Mark Neumann,
  Executive Vice President, Chief Commercial Officer
• Michael Halstead,
  Executive Vice President, General Counsel and Secretary
• Lawrence Hineline,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
• Robert Davis,
  Senior Vice President and Chief Scientific Officer
• Kimberly Vanover,
  Senior Vice President, Early Stage Clinical Development and Translational Medicines
• Dr. Sharon Mates,
  Co-Founder, Chairman, CEO & Pres
• Mark Neumann,
  EVP & Chief Commercial Officer
• Michael I. Halstead J.D.,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Suresh K. Durgam M.D.,
  Sr. VP & Chief Medical Officer
• Lawrence J. Hineline CPA, CPA,
  Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
• Robert Van Nostrand,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Christopher Alafi,
  Independent Director
• Rory Riggs,
  Independent Director
• Richard Lerner,
  Independent Director
• Michael Olchaskey,
  Senior Vice President, Head of Regulatory Affairs
• Suresh Durgam,
  Chief Medical Officer
• John Bardi,
  Senior Vice President - Market Access, Policy and Government Affairs
• Karen Patruno Sheehy Esq.,
  Sr. VP & Chief Compliance Officer
• Juan Fernando Sanchez,
  VP of Corp. Communications & Investor Relations
• Dr. Robert E. Davis Ph.D.,
  Sr. VP & Chief Scientific Officer
• Moshe Alafi,
  10% owner
• Capital Co Llc Alafi,
  10% owner
• Juan F. Sanchez,
  VP, Corp. Communications & IR
• Allen A. Fienberg,
  VP of Business Development
• Lawrence P. Wennogle,
  Vice President, Drug Discovery
• Michael Rawlins,
  Director
• Eduardo Rene Salas,
  
• Sanjeev Narula,
  Executive Vice President & CFO